24/7 Market News Snapshot 03 April, 2025 – Sangamo Therapeutics, Inc. Common Stock (NASDAQ:SGMO)

April 3, 2025

DENVER, Colo., 03 April, 2025 (247marketnews.com) – (NASDAQ:SGMO) are discussed in this article.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has recently experienced a significant uptick in stock performance, opening at $0.61 and rising to $0.851, which reflects an impressive increase of 30.28%. This growth follows a previous close of $0.653 and demonstrates heightened investor interest, underscored by a robust trading volume of 12.39 million shares. Market momentum appears to favor Sangamo, indicating bullish trends that highlight the company as a prominent player in the biotech sector.

In conjunction with this market activity, Sangamo has announced a substantial licensing agreement with Eli Lilly and Company, aimed at advancing innovative treatment solutions for neurological diseases. Through this collaboration, Lilly gains exclusive worldwide rights to Sangamo’s proprietary neurotropic adeno-associated virus (AAV) capsid, known as STAC-BBB. This capsid has shown promising preclinical results in its ability to penetrate the blood-brain barrier and facilitate neuronal transduction, which is crucial for effective treatment delivery.

The agreement entails the initial target for STAC-BBB, with options for expanding to four additional targets, positioning Lilly to develop potentially groundbreaking intravenous genomic medicines. Sangamo’s CEO, Sandy Macrae, emphasized the transformative potential of STAC-BBB in addressing critical challenges in treating neurological disorders. As part of the collaboration, Sangamo will provide a technology transfer related to STAC-BBB, while Lilly will manage research, development, and commercialization efforts.

Sangamo will receive an upfront license fee of $18 million, with opportunities to earn up to $1.4 billion through additional licensing fees and milestone payments, along with tiered royalties on future product sales. This partnership marks Sangamo’s third collaboration involving STAC-BBB and illustrates the growing momentum behind its innovative approaches to treating significant unmet medical needs in neurology, indicating a promising future for both companies in their quest to develop effective therapies.

Related news for (SGMO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.